Gender | Age
Item
women age >/= 18 years
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status of 0 or 1
boolean
C1520224 (UMLS CUI [1])
Breast adenocarcinoma Estrogen receptor negative Progesterone receptor negative HER2 Negative
Item
histologically confirmed er-, pr-, and her2-negative (triple-negative) adenocarcinoma of the breast
boolean
C0858252 (UMLS CUI [1,1])
C0279756 (UMLS CUI [1,2])
C0279766 (UMLS CUI [1,3])
C2348908 (UMLS CUI [1,4])
Availability of Tumor tissue sample
Item
confirmed availability of tumor tissue
boolean
C0470187 (UMLS CUI [1,1])
C0475358 (UMLS CUI [1,2])
Prior Therapy Quantity Secondary malignant neoplasm of female breast
Item
prior therapy with two or more regimens for metastatic breast cancer
boolean
C1514463 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0346993 (UMLS CUI [1,3])
Cancer treatment Systemic
Item
any systemic anti-cancer therapy within 3 weeks prior to day 1 of cycle 1
boolean
C0920425 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
Major surgery | Incisional biopsy | Traumatic injury
Item
major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to day 1 of cycle 1
boolean
C0679637 (UMLS CUI [1])
C0184922 (UMLS CUI [2])
C3263723 (UMLS CUI [3])
Prior Therapy Secondary malignant neoplasm of female breast | taxane
Item
prior therapy with a taxane for metastatic breast cancer
boolean
C1514463 (UMLS CUI [1,1])
C0346993 (UMLS CUI [1,2])
C0215136 (UMLS CUI [2])
Prior Therapy | bevacizumab | sorafenib | sunitinib | VEGF Pathway Targeted Therapy | Breast Carcinoma
Item
prior therapy with bevacizumab, sorafenib, sunitinib, or other putative vegf pathway-targeted therapy following diagnosis of breast cancer
boolean
C1514463 (UMLS CUI [1])
C0796392 (UMLS CUI [2])
C1516119 (UMLS CUI [3])
C1176020 (UMLS CUI [4])
C2984329 (UMLS CUI [5,1])
C2985566 (UMLS CUI [5,2])
C0678222 (UMLS CUI [6])
Prior Hormone Therapy | trastuzumab
Item
prior therapy with hormones and/or trastuzumab
boolean
C1514460 (UMLS CUI [1])
C0728747 (UMLS CUI [2])
Hematologic function Inadequate | Renal function Inadequate | Liver function Inadequate
Item
inadequate hematology, renal, or hepatic organ function
boolean
C0221130 (UMLS CUI [1,1])
C0205412 (UMLS CUI [1,2])
C0232804 (UMLS CUI [2,1])
C0205412 (UMLS CUI [2,2])
C0232741 (UMLS CUI [3,1])
C0205412 (UMLS CUI [3,2])
bevacizumab | Exclusion Criteria
Item
bevacizumab exclusion criteria
boolean
C0796392 (UMLS CUI [1])
C0680251 (UMLS CUI [2])
Uncontrolled hypertension | Systolic Pressure | Diastolic blood pressure | Antihypertensive Agents | Antihypertensive Agents Absent
Item
uncontrolled hypertension (systolic pressure > 150 mmhg and/or diastolic pressure > 100 mmhg), with or without anti-hypertensive medication
boolean
C1868885 (UMLS CUI [1])
C0871470 (UMLS CUI [2])
C0428883 (UMLS CUI [3])
C0003364 (UMLS CUI [4])
C0003364 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
Bleeding tendency | Blood Coagulation Disorders
Item
evidence of bleeding diathesis or coagulopathy
boolean
C1458140 (UMLS CUI [1])
C0005779 (UMLS CUI [2])